Navigation Links
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Date:6/8/2008

Oral presentation at international lymphoma conference shows investigational regimen resulted in 82 percent overall survival and 78

percent progression-free survival rates in patients receiving

radioimmunotherapy Confirmatory phase III clinical trial is presently being conducted in this

patient population

LUGANO, Switzerland, June 9 /PRNewswire-FirstCall/ -- In an oral presentation today at the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland, Paul A. Hamlin, M.D., of Memorial Sloan-Kettering Cancer Center, presented results of an investigator-sponsored trial of the investigational regimen consolidating rituximab-CHOP (R-CHOP) with 90Yttrium Ibritumomab Tiuxetan (Zevalin(R)) radioimmunotherapy in high risk, elderly patients with previously untreated high-intermediate and high risk diffuse large B-cell lymphoma (DLBCL). Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) markets Zevalin in the United States.

"In a high risk, elderly patient population with significant comorbidities, sequential R-CHOP followed by radioimmunotherapy resulted in excellent complete response and overall and progression-free survival rates," concluded Hamlin. "This approach is now the focus of an international phase III study."

"Improvement of relapse-free survival in these patients is an important unmet need since the outcome is poor for patients who relapse with this disease and who cannot tolerate intensive salvage therapy and stem cell transplantation," said Jack W. Singer, M.D., Chief Medical Officer at CTI. "The survival data from this study are highly encouraging compared to historical data and provide the rationale for a registration-directed randomized trial of Zevalin consolidation in higher risk patients with DLBCL."

Results of the Study

Historical studies provided as background in the presentation indicate that approximately 50 perc
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens
2. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
5. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
6. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
7. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
8. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
9. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
10. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
11. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 Quantum ... scaling volume production of photoactive quantum dots for ... . While offering numerous advantages for solar power ... large quantities of quantum dots with which to ... kept them from commercial utilization and acceptance. The ...
(Date:10/1/2014)... 1, 2014  SI-BONE, Inc., a medical device company that ... a minimally invasive surgical (MIS) device indicated for fusion for ... expansion of its European operations with the formation of a ... as General Manager, Germany.  Mr. Schaber will join former Kyphon ... Europe , Middle East ...
(Date:10/1/2014)... R.I. , Oct. 1, 2014  CVS Health ... Month for their role in changing the way health ... improve quality in the Company,s retail pharmacies, mail service ... month, we changed our company name to CVS Health ... expertise in driving the innovations needed to shape the ...
Breaking Medicine Technology:Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 2CVS Health Thanking its Pharmacists during American Pharmacists Month for Helping People on Their Path to Better Health 3
... Nov. 23 Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) ... U.S. Food and Drug Administration (FDA) on January 20, 2010 ... Application (NDA) for Intermezzo ® (zolpidem tartrate ... by Transcept on October 28, 2009, indicated that the FDA ...
... , ORANGE COUNTY, Calif., Nov. 23 ... a leading developer, manufacturer, and marketer of products that ... that Allan Harris, Beckman Coulter,s vice president of strategy, ... Wednesday, December 2, 2009 at 12:00 p.m. (ET). , ...
Cached Medicine Technology:Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter 2
(Date:10/1/2014)... October 01, 2014 First Warning Systems, ... circadian cellular changes throughout the body, announced the company ... better address the company’s breadth of upcoming product releases. ... cancer screening technology. , “Our initial focus will be ... which detects abnormal circadian cellular changes over time,” said ...
(Date:10/1/2014)... 01, 2014 Join the more than 80 ... Treatment Center’s first ever charity golf tournament to benefit Project ... eating disorders who cannot afford treatment. The tournament will be ... Eureka, Mo. , The day-long event starts with 10:30 ... and award dinner will begin at 5 p.m. and will ...
(Date:10/1/2014)... Innovations announces the upcoming airing of Innovations ... October 20, 2014 at 7:30 a.m. EST/PT via Discovery ... the scenes to learn about Break the Cycle’s comprehensive ... practical help and information Break the Cycle provides to ... of abuse, how to navigate the legal system, and ...
(Date:10/1/2014)... 2014 Scientists at the University of ... target immune system proteins has the power to knock ... details of the new study on their website. ... Researchers in the UWA School of Pathology and Laboratory ... mice with mesothelioma with promising results. , “A ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 October is ... awareness and early detection plans while raising money for ... support Breast Cancer Awareness Month in the effort ... wants to promote the importance of having access to ... water may be linked to certain forms of cancer. ...
Breaking Medicine News(10 mins):Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2
... Attorneys from Dallas, Rasansky Law Firm are ... of the mother of a 2-year-old girl who choked to death ... lawsuit includes claims that the day care,s owners quickly sold the ... from showing up on a state licensing database. , According to ...
... WAYNE, Pa., Nov. 5 Qualsec,s (OTC Bulletin ... received an order from DMC Athletics & ... business will offer products of QLSZ,s wholly-owned subsidiary, ... providing dietary support to their various wellness programs. ...
... DUE TO AN EMBARGO BREAK , From their very first days, ... speak, reveals a new study published online on November 5th in ... that infants begin picking up elements of what will be their ... babble or coo. "The dramatic finding of this study is ...
... left demanding jobs report the most improvement, study finds, , ... doing once retired seems to make a good night,s ... French workers who had retired found that the odds of ... 26 percent lower than in the seven years before they ...
... Research Institute calls for further investigations into the use of ... Nov. 5 Two studies published by the Southwest College ... Clinical Pharmacology investigated the use of oral dimercaptosuccinic acid ... lead poisoning, and used off-label in these studies for treating ...
... ... for the ClearCanvas customer base of more than 5,000 radiology software users worldwide. ... Toronto, Ontario (PRWEB) ... premier support provider for ClearCanvas, Inc. open source RIS/PACS products. Oso Healthcare ...
Cached Medicine News:Health News:The Rasansky Law Firm Announces Dallas Day Care Death Lawsuit; State Investigation Finds Evidence of Negligence at Woodbridge Day School 2Health News:Qualsec's Wholly-Owned Subsidiary Receives Order From New Jersey-Based DMC Athletics and Rehabilitation 2Health News:Babies' language learning starts from the womb 2Health News:Without Job Stress, Retirees Sleep Better 2Health News:Chelation Therapy Drug Found Safe and Beneficial for Children With Autism 2Health News:Oso Healthcare Provides Implementation and Support Services for ClearCanvas Open Source RIS/PACS 2Health News:Oso Healthcare Provides Implementation and Support Services for ClearCanvas Open Source RIS/PACS 3Health News:Oso Healthcare Provides Implementation and Support Services for ClearCanvas Open Source RIS/PACS 4
Help restore pelvic muscle function with the Prometheus Pathway CTS 2000 evaluation and training system....
... catheters with secondary sensors placed in the ... test also provides information about acid control ... stomach or proximal esophageal acid exposure and ... Ability to record pH simultaneously in up ...
... the advance of digital imaging technology, ... towards digital formats, allowing for easier ... advance in digital pathology imaging is ... in radiology, and which is continuing ...
... SONOLINE G40 ultrasound system brings,the benefits ... entirely new level of diagnostic performance,and ... that meets your clinical needs. With ... and pulsed-wave Doppler capabilities,the G40 system ...
Medicine Products: